Akeso Management

Management Kriterienprüfungen 4/4

Akeso CEO ist Michelle Xia , ernannt in Mar 2012, hat eine Amtszeit von 13.17 Jahren. Die jährliche Gesamtvergütung beträgt CN¥5.55M , bestehend aus 85.4% Gehalt und 14.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 8.53% der Aktien des Unternehmens, im Wert von HK$6.45B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.5 Jahre bzw. 5.5 Jahre.

Wichtige Informationen

Michelle Xia

Geschäftsführender

CN¥5.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	85.4%
Amtszeit als Geschäftsführer	13.2yrs
Eigentum des Geschäftsführers	8.5%
Durchschnittliche Amtszeit des Managements	2.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.5yrs

Jüngste Management Updates

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 24

Recent updates

Akeso, Inc.'s (HKG:9926) Shares Climb 29% But Its Business Is Yet to Catch Up

May 07

Earnings Update: Here's Why Analysts Just Lifted Their Akeso, Inc. (HKG:9926) Price Target To HK$104

May 03

Cadonilimab And Ivonescimab Trials Will Broaden Market Access

Apr 06 Akeso's strategic focus on bispecific antibodies and NRDL inclusion could drive significant revenue growth and expand market access.

Earnings Update: Here's Why Analysts Just Lifted Their Akeso, Inc. (HKG:9926) Price Target To HK$82.91

Apr 01

Akeso, Inc.'s (HKG:9926) Shares Climb 28% But Its Business Is Yet to Catch Up

Mar 16

Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking

Sep 09

Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Aug 30

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 24

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Jun 19

Are Investors Undervaluing Akeso, Inc. (HKG:9926) By 43%?

May 31

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Michelle Xia im Vergleich zu den Einnahmen von Akeso verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2024	CN¥6m	CN¥5m	-CN¥515m
Sep 30 2024	n/a	n/a	-CN¥625m
Jun 30 2024	n/a	n/a	-CN¥735m
Mar 31 2024	n/a	n/a	CN¥646m
Dec 31 2023	CN¥7m	CN¥4m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥409m
Dec 31 2022	CN¥5m	CN¥4m	-CN¥1b
Sep 30 2022	n/a	n/a	-CN¥1b
Jun 30 2022	n/a	n/a	-CN¥1b
Mar 31 2022	n/a	n/a	-CN¥1b
Dec 31 2021	CN¥7m	CN¥4m	-CN¥1b
Sep 30 2021	n/a	n/a	-CN¥1b
Jun 30 2021	n/a	n/a	-CN¥929m
Mar 31 2021	n/a	n/a	-CN¥983m
Dec 31 2020	CN¥7m	CN¥3m	-CN¥1b
Sep 30 2020	n/a	n/a	-CN¥870m
Jun 30 2020	n/a	n/a	-CN¥703m
Mar 31 2020	n/a	n/a	-CN¥492m
Dec 31 2019	CN¥2m	CN¥1m	-CN¥282m

Vergütung im Vergleich zum Markt: MichelleDie Gesamtvergütung ($USD766.56K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD705.31K).

Entschädigung vs. Einkommen: MichelleDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Michelle Xia (57 yo)

13.2yrs

Amtszeit

CN¥5,548,000

Vergütung

Dr. Yu Xia, Ph D., also known as Michelle, is CEO & President of Akeso Biopharma, Inc. Dr. Xia is Founder of Akeso, Inc. Dr. Xia is CEO, President & Chairwoman of Akeso, Inc. from March 19, 2012. She has b...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Yu Xia	Founder	13.2yrs	CN¥5.55m	8.53% HK$ 6.5b
Baiyong Li	Co-Founder	13.2yrs	CN¥5.28m	5.65% HK$ 4.3b
Zhongmin Wang	Co-Founder	no data	CN¥3.96m	4.81% HK$ 3.6b
Peng Zhang	Co-Founder	no data	CN¥3.83m	keine Daten
Yu Xia	Senior Vice President	less than a year	CN¥9.33m	keine Daten
Bing Wang	Chief Financial Officer	less than a year	keine Daten	keine Daten
Xinfeng Zhang	Senior Vice President	4.8yrs	keine Daten	keine Daten
Mingxiu Hu	Senior Vice President	3.3yrs	keine Daten	keine Daten
Charlie Zhang	Senior Vice President	2.3yrs	keine Daten	keine Daten
Jing Min	Senior Vice President	2.3yrs	keine Daten	keine Daten
Yong Guo	Senior VP & Chief Commercial Officer	1.3yrs	keine Daten	keine Daten
Wai Yan Leung	Company Secretary	2.8yrs	keine Daten	keine Daten

2.5yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: 9926Das Führungsteam des Unternehmens gilt als erfahren (2.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Yu Xia	Founder	13.2yrs	CN¥5.55m	8.53% HK$ 6.5b
Baiyong Li	Co-Founder	5.5yrs	CN¥5.28m	5.65% HK$ 4.3b
Zhongmin Wang	Co-Founder	5.5yrs	CN¥3.96m	4.81% HK$ 3.6b
Peng Zhang	Co-Founder	less than a year	CN¥3.83m	keine Daten
Bo Tan	Independent Non-Executive Director	no data	CN¥320.00k	keine Daten
Ronggang Xie	Non-Executive Director	4.8yrs	keine Daten	keine Daten
Yan Xu	Independent Non-Executive Director	no data	CN¥320.00k	keine Daten
Junwen Zeng	Independent Non-Executive Director	no data	CN¥320.00k	keine Daten

5.5yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrener Vorstand: 9926Die Vorstandsmitglieder gelten als erfahren (5.5 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/05/08 16:56
Aktienkurs zum Tagesende	2025/05/08 00:00
Gewinne	2024/12/31
Jährliche Einnahmen	2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Akeso, Inc. wird von 40 Analysten beobachtet. 20 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Sharon Shi	BOCI Research Ltd.
Jiangqiao Tong	BOCI Research Ltd.
Yonglin Yan	BOCI Research Ltd.

Akeso Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Co-Founder recently sold HK$214m worth of stock

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

Akeso, Inc. Announces Change of Directors

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Founder recently sold HK$96m worth of stock

Recent updates

Akeso, Inc.'s (HKG:9926) Shares Climb 29% But Its Business Is Yet to Catch Up

Earnings Update: Here's Why Analysts Just Lifted Their Akeso, Inc. (HKG:9926) Price Target To HK$104

Full year 2024 earnings: EPS and revenues miss analyst expectations

Now 28% undervalued

Akeso, Inc. Announces Its Globally First-In-Class PD-1/VEGF Bispecific Antibody, Ivonescimab, Received Approval from the National Medical Products Administration

Akeso, Inc. Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

Summit Therapeutics Inc. Announces Phase Iii Clinical Trial, Harmoni-6

Akeso's Ebdarokimab Receives Marketing Approval from the National Medical Products Administration

New minor risk - Share price stability

Cadonilimab And Ivonescimab Trials Will Broaden Market Access

Earnings Update: Here's Why Analysts Just Lifted Their Akeso, Inc. (HKG:9926) Price Target To HK$82.91

Full year 2024 earnings released: CN¥0.60 loss per share (vs CN¥2.42 profit in FY 2023)

Akeso, Inc. to Report Fiscal Year 2024 Results on Mar 30, 2025

Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

Akeso, Inc.'s (HKG:9926) Shares Climb 28% But Its Business Is Yet to Catch Up

Akeso, Inc. Announces the Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet

Akeso Announces Completion of Patient Enrollment in the Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

Akeso, Inc. Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

Akeso, Inc. Enrolles First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer

Akeso, Inc. Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Ra and ST2 for Respiratory and Skin Diseases

Akeso, Inc. Announces Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Current or Sequential Chemoradiotherapy in NSCLC

Akeso, Inc. Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab

Akeso, Inc.'s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accept by NMPA

Akeso, Inc. Publishes Results for Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer

Co-Founder recently sold HK$214m worth of stock

Akeso Announces the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab

Akeso, Inc.'s Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma Accepted by NMPA

Akeso, Inc. Publishes Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.942576 billion.

Akeso Biopharma Announces Positive Results in Progression-Free Survival (PFS) and Overall Survival (OS) from Its Phase 3 Clinical Study

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population

Akeso, Inc. Secures Approval from China’s National Medical Products Administration for Ebronucimab, Expanding Treatment Options for Hypercholesterolemia

Akeso's Ivonescimab Plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety At ESMO 2024

Optimistic Investors Push Akeso, Inc. (HKG:9926) Shares Up 27% But Growth Is Lacking

Consensus EPS estimates upgraded to CN¥0.43 loss

Akeso, Inc. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

First half 2024 earnings released: CN¥0.28 loss per share (vs CN¥3.02 profit in 1H 2023)

Akeso, Inc. to Report Q2, 2024 Results on Aug 28, 2024

Akeso, Inc. Announces Ivonescimab (Pd-1/Vegf) Received Priority Review from China's Nmpa for First-Line Treatment of Pd-L1 Positive Nsclc

Akeso, Inc. Announces That the First Patient Enrolled in the US Phase 2 Combination Therapy of it's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

Akeso's Sbla for Ivonescimab in 1L Treatment of Pd-L1 Positive Nsclc Accepted by NMPA

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

New major risk - Share price stability

Akeso, Inc. Announces Change of Directors

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival

Are Investors Undervaluing Akeso, Inc. (HKG:9926) By 43%?

New minor risk - Share price stability

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

Investor sentiment deteriorates as stock falls 24%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock